Imatinib Mesylate and Paclitaxel [clinicaltrials_resource:NCT01011075/group/O1]
Experimental: Treatment (enzyme inhibitor, chemotherapy) Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
group [clinicaltrials_vocabulary:group]
NCT01011075 measurement [clinicaltrials_resource:NCT01011075/measurement/2fc67b9b9e0d98b11c71d1a58b9bf336]NCT01011075 measurement [clinicaltrials_resource:NCT01011075/measurement/4baf74629afce6e777ec4292b772b4f7]NCT01011075 measurement [clinicaltrials_resource:NCT01011075/measurement/4bc41e9aa52e9c8520e8f2225219923b]NCT01011075 measurement [clinicaltrials_resource:NCT01011075/measurement/559e3a78233161a736d7f95b287eae0d]NCT01011075 measurement [clinicaltrials_resource:NCT01011075/measurement/b00f757528f3913de2800523bd8fe6e6]
group id [clinicaltrials_vocabulary:group-id]
Imatinib Mesylate and Paclitaxel [clinicaltrials_resource:NCT01011075/group/O1]
Experimental: Treatment (enzyme inhibitor, chemotherapy) Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
NCT01011075/group/O1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT01011075/group/O1
group id [clinicaltrials_vocabulary:group-id]
description
Experimental: Treatment (enzym ...... sion or unacceptable toxicity.
@en
identifier
clinicaltrials_resource:NCT01011075/group/O1
title
Imatinib Mesylate and Paclitaxel
@en
type
label
Imatinib Mesylate and Paclitaxel [clinicaltrials_resource:NCT01011075/group/O1]
@en